X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
natalizumab (357) 357
humans (333) 333
index medicus (296) 296
multiple sclerosis (188) 188
female (165) 165
male (146) 146
adult (136) 136
progressive multifocal leukoencephalopathy (125) 125
middle aged (113) 113
clinical neurology (111) 111
multiple sclerosis - drug therapy (110) 110
animals (107) 107
neurosciences (101) 101
immunology (81) 81
neurology (80) 80
antibodies, monoclonal - therapeutic use (72) 72
antibodies, monoclonal, humanized (71) 71
antibodies, monoclonal, humanized - therapeutic use (69) 69
multiple-sclerosis (53) 53
therapy (52) 52
multiple sclerosis - immunology (51) 51
disease (50) 50
pharmacology & pharmacy (50) 50
treatment outcome (49) 49
lymphocytes (47) 47
mice (47) 47
multiple sclerosis, relapsing-remitting - drug therapy (45) 45
young adult (43) 43
immunologic factors - therapeutic use (41) 41
placebo-controlled trial (40) 40
care and treatment (39) 39
integrins (39) 39
abridged index medicus (36) 36
analysis (36) 36
experimental autoimmune encephalomyelitis (36) 36
multiple sclerosis - metabolism (36) 36
multiple sclerosis - pathology (36) 36
natalizumab - therapeutic use (35) 35
expression (34) 34
inflammation (34) 34
cerebrospinal-fluid (33) 33
risk factors (33) 33
aged (31) 31
health aspects (31) 31
central-nervous-system (29) 29
integrin alpha4 - metabolism (29) 29
t-cells (29) 29
article (28) 28
crohn's disease (28) 28
interferon (28) 28
jc virus (28) 28
magnetic resonance imaging (28) 28
pathogenesis (28) 28
research (28) 28
monoclonal antibodies (27) 27
risk (27) 27
t cells (27) 27
flow cytometry (26) 26
immunosuppressive agents - therapeutic use (26) 26
integrin alpha4 - immunology (26) 26
medicine (26) 26
multiple sclerosis - blood (26) 26
antibodies, monoclonal - adverse effects (25) 25
brain (25) 25
integrin (25) 25
research article (25) 25
allergy and immunology (24) 24
antibodies (24) 24
antibodies, monoclonal, humanized - adverse effects (24) 24
brain - pathology (24) 24
double-blind (24) 24
gastroenterology & hepatology (24) 24
infliximab (24) 24
leukoencephalopathy, progressive multifocal - chemically induced (24) 24
multidisciplinary sciences (24) 24
virology (24) 24
drug therapy (23) 23
fingolimod (23) 23
glatiramer acetate (23) 23
infection (23) 23
medicine & public health (23) 23
patients (23) 23
adolescent (22) 22
antibodies, monoclonal - pharmacology (22) 22
cell movement - drug effects (21) 21
controlled trial (21) 21
inflammatory-bowel-disease (21) 21
integrin alpha4beta1 - antagonists & inhibitors (21) 21
science (21) 21
antigens (20) 20
crohn disease - drug therapy (20) 20
cytokines (20) 20
disease models, animal (20) 20
inflammatory bowel disease (20) 20
adhesion (19) 19
biomarkers (19) 19
immunosuppressive agents - adverse effects (19) 19
jc virus - metabolism (19) 19
maintenance therapy (19) 19
multiple sclerosis, relapsing-remitting - immunology (19) 19
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 03/2014, Volume 9, Issue 3, p. e92872
Background: Pathological destruction of blood-brain barrier (BBB) has been thought to be the initial key event in the process of developing multiple sclerosis... 
IMMUNE | PHASES | WHITE-MATTER | MULTIDISCIPLINARY SCIENCES | MATRIX-METALLOPROTEINASE-9 | NATALIZUMAB | CLINICAL-COURSE | EXPRESSION | LESIONS | Multiple Sclerosis, Relapsing-Remitting - pathology | Autoantibodies - metabolism | Multiple Sclerosis, Relapsing-Remitting - blood | Serum - metabolism | Endothelial Cells - metabolism | Matrix Metalloproteinase 2 - metabolism | Humans | Cells, Cultured | Claudin-5 - metabolism | Multiple Sclerosis, Chronic Progressive - pathology | Multiple Sclerosis, Chronic Progressive - blood | Multiple Sclerosis, Chronic Progressive - metabolism | Blood-Brain Barrier - metabolism | Brain - metabolism | Blood-Brain Barrier - pathology | Matrix Metalloproteinase 9 - metabolism | Brain - pathology | Endothelial Cells - pathology | Vascular Cell Adhesion Molecule-1 - metabolism | Multiple Sclerosis, Relapsing-Remitting - metabolism | Immunoglobulin G - metabolism | Proteins | Autoimmunity | Development and progression | Multiple sclerosis | Autoantibodies | Immunoglobulin G | Neurosciences | Immunoglobulins | Vascular cell adhesion molecule 1 | Nuclear magnetic resonance--NMR | Secretion | Nervous system | Patients | Endothelial cells | Cell adhesion & migration | Gelatinase A | Medicine | Neurology | Molecular modelling | Blood-brain barrier | Breakdowns | Cell adhesion | Microvasculature | Autocrine signalling | University graduates | NMR | Nuclear magnetic resonance
Journal Article
Journal Article
Neurotherapeutics, ISSN 1933-7213, 1/2017, Volume 14, Issue 1, pp. 199 - 211
Journal Article
Immunological Investigations, ISSN 0882-0139, 10/2015, Volume 44, Issue 7, pp. 694 - 712
Background and Purpose: Some functional limitations and economic burden of therapeutic antibodies indicated that introducing of alternative therapeutic... 
EAE | neuro-inflammation | VLA4 | BIO-1211 | multiple sclerosis | CORTICAL DEMYELINATION | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | DIFFERENT SUBTYPES | C57BL/6 MICE | NATALIZUMAB | IMMUNOLOGY | B-CELLS | IN-VIVO | ANIMAL-MODEL | IRANIAN PATIENTS | T-CELLS | Leukocyte Common Antigens - metabolism | Encephalomyelitis, Autoimmune, Experimental - metabolism | Cerebral Cortex - pathology | Encephalomyelitis, Autoimmune, Experimental - immunology | Male | Monocytes - metabolism | Thiazoles - administration & dosage | Monocytes - immunology | RNA, Messenger - metabolism | Cerebral Cortex - metabolism | Cell Movement - immunology | Leukocytes - immunology | Inflammation Mediators - metabolism | Encephalomyelitis, Autoimmune, Experimental - genetics | Cytokines - genetics | Oligopeptides - chemistry | Disease Models, Animal | Multiple Sclerosis - metabolism | Permeability - drug effects | Encephalomyelitis, Autoimmune, Experimental - pathology | Cytokines - metabolism | Encephalomyelitis, Autoimmune, Experimental - drug therapy | RNA, Messenger - genetics | Multiple Sclerosis - genetics | Blood-Brain Barrier - drug effects | Disease Progression | Blood-Brain Barrier - metabolism | Gene Expression Regulation - drug effects | Animals | Cerebral Cortex - immunology | Integrin alpha4beta1 - antagonists & inhibitors | Multiple Sclerosis - immunology | Multiple Sclerosis - pathology | Mice | Oligopeptides - administration & dosage | Thiazoles - pharmacology | CD11b Antigen - metabolism | Oligopeptides - pharmacology | Leukocytes - metabolism | Multiple Sclerosis - drug therapy
Journal Article
Expert Opinion on Pharmacotherapy, ISSN 1465-6566, 03/2018, Volume 19, Issue 5, pp. 483 - 498
Introduction: Multiple sclerosis (MS) is an immune-mediated and neurodegenerative disease with an unpredictable outcome. Immune-modulatory treatment aims at... 
interferon beta | Multiple sclerosis | ocrelizumab | dimethylfumarate | alemtuzumab | cladribine | fingolimod | teriflunomide | glatiramer acetate | natalizumab | daclizumab | HIGH-YIELD PROCESS | CONTROLLED PHASE-3 | GRANULE CELL NEURONOPATHY | FUMARIC-ACID ESTERS | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | VARICELLA-ZOSTER-VIRUS | INTERFERON-BETA THERAPY | TERM-FOLLOW-UP | PHARMACOLOGY & PHARMACY | PLACEBO-CONTROLLED TRIAL | DISEASE-MODIFYING THERAPIES | Alemtuzumab - adverse effects | Neoplasms - etiology | Crotonates - metabolism | Alemtuzumab - metabolism | Humans | Immunosuppressive Agents - therapeutic use | Natalizumab - adverse effects | Natalizumab - metabolism | Interferon-beta - therapeutic use | Interferon-beta - adverse effects | Natalizumab - therapeutic use | Fingolimod Hydrochloride - adverse effects | Fingolimod Hydrochloride - therapeutic use | Toluidines - therapeutic use | Toluidines - metabolism | Toluidines - adverse effects | Fingolimod Hydrochloride - metabolism | Crotonates - therapeutic use | Glatiramer Acetate - adverse effects | Cladribine - metabolism | Interferon-beta - metabolism | Cladribine - therapeutic use | Glatiramer Acetate - therapeutic use | Multiple Sclerosis - pathology | Glatiramer Acetate - metabolism | Immunosuppressive Agents - adverse effects | Immunologic Factors - adverse effects | Cladribine - adverse effects | Crotonates - adverse effects | Alemtuzumab - therapeutic use | Immunologic Factors - therapeutic use | Multiple Sclerosis - drug therapy
Journal Article
Journal Article
Multiple Sclerosis Journal, ISSN 1352-4585, 4/2013, Volume 19, Issue 5, pp. 543 - 552
Background:Amyloid precursor protein (APP) and amyloid β (Aβ) peptides are intensely studied in neuroscience and their cerebrospinal fluid (CSF) measurements... 
mitoxantrone | Amyloid beta | amyloid precursor protein | biomarkers | multiple sclerosis | relapsing-remitting MS | APP metabolism | cerebrospinal fluid | secondary progressive MS | natalizumab | MYELINATION | TAU | NEUROSCIENCES | CLINICAL NEUROLOGY | DISABILITY | PRECURSOR PROTEIN | Central Nervous System Agents - therapeutic use | Immunoassay | Immunoprecipitation | Natalizumab | Humans | Middle Aged | Male | Case-Control Studies | Tandem Mass Spectrometry | Amyloid beta-Protein Precursor - cerebrospinal fluid | Mass Spectrometry | Amyloid beta-Peptides - metabolism | Amyloid beta-Protein Precursor - metabolism | Amyloid beta-Peptides - cerebrospinal fluid | Chromatography, Liquid | Adult | Female | Multiple Sclerosis, Chronic Progressive - drug therapy | Mitoxantrone - therapeutic use | Multiple Sclerosis, Relapsing-Remitting - metabolism | Multiple Sclerosis - metabolism | Biomarkers - metabolism | Multiple Sclerosis, Chronic Progressive - cerebrospinal fluid | Peptide Fragments - metabolism | Antibodies, Monoclonal, Humanized - therapeutic use | Peptide Fragments - cerebrospinal fluid | Multiple Sclerosis - cerebrospinal fluid | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Multiple Sclerosis, Chronic Progressive - metabolism | Amyloid beta-Peptides - chemistry | Biomarkers - cerebrospinal fluid | Multiple Sclerosis, Relapsing-Remitting - cerebrospinal fluid | Multiple Sclerosis - drug therapy | Neurosciences | Neurovetenskaper | relapsing–remitting MS
Journal Article
Journal Article
Bone Marrow Transplantation, ISSN 0268-3369, 10/2010, Volume 45, Issue 10, pp. 1489 - 1496
Therapeutic application of natalizumab, an anti-CD49d Ab, in patients with multiple sclerosis (MS) has been associated with increased levels of circulating... 
hematopoietic stem and progenitor cells | migration | mobilization | G-CSF | natalizumab | STEM-CELLS | COLONY-STIMULATING FACTOR | FILGRASTIM | PERIPHERAL-BLOOD | IMMUNOLOGY | TRANSPLANTATION | ANTIBODY NATALIZUMAB | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | MARROW CD34(+) CELLS | ONCOLOGY | HEMATOLOGY | EXPRESSION | Antigens, CD34 - metabolism | Multiple Sclerosis - blood | Natalizumab | Erythroid Precursor Cells - drug effects | Humans | Immunosuppressive Agents - therapeutic use | Glycoproteins - metabolism | Homeostasis | Antibodies, Monoclonal - therapeutic use | Male | RNA, Messenger - metabolism | Erythroid Precursor Cells - physiology | Antigens, CD - metabolism | Hematopoiesis - drug effects | Antibodies, Monoclonal, Humanized | Matrix Metalloproteinase 9 - metabolism | Cyclin-Dependent Kinase Inhibitor p21 - genetics | Peptides - metabolism | Matrix Metalloproteinase 9 - genetics | Cyclin-Dependent Kinase Inhibitor p21 - metabolism | Hematopoietic Stem Cells - physiology | Adult | Female | Hematopoietic Stem Cell Mobilization | Multiple Sclerosis - metabolism | Hematopoietic Stem Cells - drug effects | Immunophenotyping | AC133 Antigen | Antigens, CD34 - blood | Integrin alpha4 - immunology | Cell Movement - drug effects | Bone Marrow Cells - metabolism | Multiple Sclerosis - drug therapy | Complications and side effects | Multiple sclerosis | Granulocyte colony-stimulating factor | Transplantation | Research | Drug therapy | Health aspects | Hematopoietic stem cells | Risk factors
Journal Article
European Neurology, ISSN 0014-3022, 05/2010, Volume 63, Issue 5, pp. 311 - 317
Journal Article
Journal of the American Heart Association, ISSN 2047-9980, 07/2015, Volume 4, Issue 7
Cardiovascular disease (CVD), myocarditis and fibrosis are comorbidities of HIV(+) individuals on durable antiretroviral therapy (ART). Although mechanisms for... 
fibrosis | HIV | animal model | cardiomyopathy | myocarditis | Simian Acquired Immunodeficiency Syndrome - metabolism | Myocardium - immunology | Cardiomyopathies - prevention & control | Monocytes - metabolism | Macaca mulatta | Monocytes - immunology | Myocarditis - diagnosis | Antigens, CD - metabolism | Simian Acquired Immunodeficiency Syndrome - virology | Macrophages - virology | Time Factors | Myocardium - metabolism | Cardiomyopathies - diagnosis | Myocarditis - prevention & control | Myocarditis - immunology | Cardiomyopathies - immunology | Macrophages - immunology | Cytoprotection | Disease Models, Animal | Simian Immunodeficiency Virus - immunology | Simian Acquired Immunodeficiency Syndrome - diagnosis | Simian Immunodeficiency Virus - pathogenicity | Receptors, Cell Surface - metabolism | Myocardium - pathology | Chemotaxis - drug effects | Integrin alpha4 - immunology | Monocytes - drug effects | Monocytes - virology | Myocarditis - virology | Macrophages - metabolism | Animals | Cardiomyopathies - virology | Integrin alpha4 - metabolism | Natalizumab - pharmacology | Simian Acquired Immunodeficiency Syndrome - drug therapy | Simian Acquired Immunodeficiency Syndrome - immunology | CD8-Positive T-Lymphocytes - virology | Antigens, Differentiation, Myelomonocytic - metabolism | Cardiomyopathies - metabolism | Fibrosis | Myocarditis - metabolism | Macrophages - drug effects | Immunocompromised Host | CD8-Positive T-Lymphocytes - immunology | Immunologic Factors - pharmacology
Journal Article